Clinical Trials

Obesity in patients who have had a heart attack or stroke

Posted on 12/30/2018
Research has shown that treatment with semaglutide (an FDA approved drug) may reduce the risk of stroke and heart attack in people with type 2 diabetes.  The purpose of this study is to assess whether semaglutide reduces the risk of heart attack and stroke in people who are overweight or obese.

You may qualify to participate in this study if:
  • You have had a stroke or heart attack, or have poor circulation (peripheral arterial disease)
  • You are 45 years of age or older
  • You are overweight or obese
  • You are able to attend regular clinic visits and receive phone calls over a period of 3-5 years

If you qualify for this study, you will receive study-related care, including regular health check-ups and guidance on healthy lifestyle choices.  You will also be compensated $50 for every clinic visit you attend up to $1,250.  
What Our Research Patients are Saying
"I was on edge when I first went to DCOL Research because of the sensitive nature of my diagnosis. Upon arrival to the research office I was treated very kindly and professionally as soon as I signed in. The Research Coordinator was friendly and compassionate and made me feel at ease. I was informed about the trial and they ensured that I had a clear understanding of the information. During all my visits I felt at ease and informed. The Research Coordinator is very professional as is the Lab Coordinator. It is always a smooth process and the staff is confident and friendly. The study doctor is also helpful and always asks if I have any problems or concerns, just like the staff."

~ Anonymous

Contact Form


  
DCOL of Longview